Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antineoplastons A10 and AS2-1 in Children With Brain Tumors
NCT00003458Phase 2
Key facts
- Status
- Completed
- Start
- Sep 1996
- Primary completion
- Sep 2014
- Countries
- 1
- Sponsor
- Burzynski Research Institute
- Modality
- Peptides, Small Molecules
- Conditions
- brain tumor
01
Overview
Phase 2, open-label, single-arm trial of antineoplaston A10 and antineoplaston AS2-1 in brain tumor, sponsored by Burzynski Research Institute. Primary endpoint: Objective Response at 12 months. Started Sep 1996; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Antineoplaston therapy
Atengenal + Astugenal by IV infusion every four hours
03
Who it enrols
Children aged 6 months to 17 years with histologically confirmed, measurable brain tumors for which no curative therapy exists, with adequate organ function and performance status.
04
Endpoints
Primary
Objective Response
Secondary
Overall Survival
Beyond the preview
Go deeper on NCT00003458.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003458.